Wednesday 20th November 2013 at 3 pm GMT, 4 pm CET, 10 am EST In response to the challenges of new product formats and increased regulatory scrutiny, the early developability of biotherapeutic candidates based on stability and formulation characteristics is becoming ever more important. This interactive webinar, brought to you by Avacta Analytical and Synthon Biopharmaceuticals, will address the themes and challenges in this area. Read more:
Wednesday 20th November 2013 at 3 pm GMT, 4 pm CET, 10 am EST
In response to the challenges of new product formats and increased regulatory scrutiny, the early developability of biotherapeutic candidates based on stability and formulation characteristics is becoming ever more important. This interactive webinar, brought to you by Avacta Analytical and Synthon Biopharmaceuticals, will address the themes and challenges in this area.
The webinar will demonstrate how high throughput protein thermal stability analysis is widely used as a predictive tool to accelerate formulation development and candidate selection, or to optimise processing conditions downstream. It will focus on the formulation of a monoclonal antibody and the capabilities of high throughput screening to predict degradation, characterise stability and enhance workflows, as well as offering a case study in an industrial setting.
Click here to learn more and to register.
Meeting Secondary Packaging Challenges of Innovative Delivery Systems for Biologics
February 6th 2025Rapid market growth in biologics is helping the packaging market expand as well, but the complex nature of biologics and the desire for personalized therapies present unique hurdles to make packaging solutions cost-effective and safe for patients.